Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial

BACKGROUND: In the EMPA-REG OUTCOME trial (BI 10773 [Empagliflozin] Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) in patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease, in comparison with placebo, empagliflozin reduced the risks of 3-point ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Fitchett, David, Inzucchi, Silvio E., Cannon, Christopher P., McGuire, Darren K., Scirica, Benjamin M., Johansen, Odd Erik, Sambevski, Steven, Kaspers, Stefan, Pfarr, Egon, George, Jyothis T., Zinman, Bernard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416009/
https://www.ncbi.nlm.nih.gov/pubmed/30586757
http://dx.doi.org/10.1161/CIRCULATIONAHA.118.037778

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416009/
https://www.ncbi.nlm.nih.gov/pubmed/30586757
http://dx.doi.org/10.1161/CIRCULATIONAHA.118.037778

Ejemplares similares